Skip to main content
BIOXYNE LIMITED logo

BIOXYNE LIMITED — Investor Relations & Filings

Ticker · BXN ISIN · AU000000BXN6 LEI · 984500F02D2B1B94E956 ASX Manufacturing
Open in API
Filings indexed 844 across all filing types
Latest filing 2008-04-29 Interim / Quarterly Rep…
Country AU Australia
Listing ASX BXN

About BIOXYNE LIMITED

https://bioxyne.com

Bioxyne Limited is a life sciences company focused on the development, manufacture, and commercialization of health and wellness products. The company specializes in proprietary probiotic strains, notably the Lactobacillus fermentum VRI-003 (PCC), which is utilized in supplements targeting immune health and gut function. Following the acquisition of Breathe Life Sciences, Bioxyne has expanded its portfolio into the medicinal cannabis sector, novel foods, and consumer health products. Its operations encompass the production and distribution of pharmaceutical-grade cannabis products, CBD-based wellness items, and functional supplements. The company serves international markets through a vertically integrated model, focusing on research-driven formulations and high-quality manufacturing standards to address growing consumer demand for therapeutic and preventative health solutions.

Recent filings

Filing Released Lang Actions
Commitments Test Entity - Third Quarter Report 6 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C - Quarterly cash report' and is addressed to the ASX Companies Announcements Office. It contains detailed quarterly cash flow statements, including operating, investing, and financing activities for the quarter ended 31 March 2008. The document also discusses a Share Purchase Plan (SPP) and includes compliance statements related to accounting standards. The presence of detailed financial data for a quarter and the nature of the report align with a quarterly financial report. The document is not an announcement of a report but the report itself, given its length (over 14,000 characters) and detailed financial content. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2008
2008-04-29 English
Extension of Share Purchase Plan 1 page ?Kb
Capital/Financing Update Classification · 95% confidence The document is a short announcement dated 24 April 2008 from Probiomics Limited regarding the extension of a Share Purchase Plan (SPP). It references a previous ASX release and provides a revised closing date for the offer. There is no financial data, detailed report, or management discussion present. The content focuses on a financing activity related to shareholder investment opportunities. Given the nature of the announcement about extending a share purchase plan, it fits best under Capital/Financing Update (CAP). The document length is short and does not contain a full report or financial statements, so it is not an Annual Report or Interim Report. It is not a Regulatory Filing or Report Publication Announcement since it contains substantive update information rather than just a notice of report availability.
2008-04-23 English
Extension of Share Purchase Plan Offer 1 page ?Kb
Capital/Financing Update Classification · 95% confidence The document is a short announcement dated 18 April 2008 from Probiomics Limited regarding the extension of a Share Purchase Plan (SPP) offer by two weeks. It mentions the offer closing date and references a market update related to a proposed acquisition. The document is brief (1315 characters) and serves as an update on a financing activity (share purchase plan extension). It does not contain financial statements or detailed financial data, nor is it a full report or regulatory certification. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2008-04-17 English
Market Update - Acquisition of Minomic International Limited 2 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is a market update from Probiomics Limited dated 16 April 2008, providing information about the acquisition of Minomic International Limited and progress on diagnostic tests for prostate cancer and type 2 diabetes. It discusses milestones, clinical trials, and market potential but does not contain financial statements or detailed financial performance data. The document is an announcement updating shareholders and the market on a corporate transaction and business progress rather than a full financial report or regulatory filing. It is not a full Annual Report, Interim Report, or Earnings Release. It is also not a formal M&A filing but an update related to acquisition activity. Given the content and length (4110 characters), it fits best as a Capital/Financing Update (CAP) because it relates to acquisition and shareholder offer updates. Confidence is high due to clear focus on acquisition and shareholder information without financial statements.
2008-04-15 English
Market Update 1 page ?Kb
Capital/Financing Update Classification · 95% confidence The document is a short market update letter from the company to the ASX Companies Announcements Office. It discusses recent market volatility related to a third party's receivership, confirms no shares were involved in agreements, and mentions commitment to a Share Purchase Plan and a pending acquisition subject to shareholder approval. The document is only 1204 characters long, which is very short and does not contain detailed financial data or comprehensive reporting. It is an announcement providing an update on financing and capital activities, specifically mentioning a Share Purchase Plan (SPP) and acquisition plans. Therefore, it fits best under Capital/Financing Update (CAP).
2008-04-06 English
Newsletter 3 pages ?Kb
Investor Presentation Classification · 90% confidence The document is a newsletter from Probiomics Limited dated 20 March 2008. It provides an update to shareholders on company progress, including a chairman's message, capital raising activity, a major licensing agreement with Nestlé, and a proposed acquisition of Minomic International Limited. The content focuses on business updates, strategic developments, and shareholder information rather than detailed financial statements or regulatory filings. The document is not a formal annual or interim report, audit report, earnings release, or regulatory filing. It is a communication to shareholders providing corporate updates and encouraging participation in a Shareholder Purchase Plan. This fits the profile of an Investor Presentation or shareholder update document. Given the detailed business and financial strategy information aimed at investors, the best classification is Investor Presentation (IP).
2008-03-19 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.